Amgen Highlights Effects Of Health Reform Provisions In Earnings Call
While Amgen's bottom line will take a hit in the wake of the new health care reform law, the impact is expected to minimal enough that officials did not have to change previously reported guidance
You may also be interested in...
Amgen says health care reform will trim its sails, but it's not much compared to the blow it took from the ESA safety problems.
Strategies To Ease Short-Term Earnings Pain From Health Reform Include Cost-Cutting, Diversification
With market-based fees and increased Medicaid rebates set to start several years before drug manufacturers will see any benefit of an expanded market from health care reform, consultants are suggesting several ways to counter the short-term negative effect on earnings, including continued cost-cutting and diversification
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011